Change in Newron Board of Directors

Newron Pharmaceuticals SpA / Key word(s): Personnel

01-Dec-2021 / 17:46 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Milan, Italy – Dec. 1, 2021 – Newron Pharmaceuticals S.p.A. (‘Newron’, SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Directors of his intention to step down as a Non-Executive member of the Board of Directors, effective December 31, 2021.

Ulrich Köstlin, Chairman of Newron, commented: ‘The Board of Directors and I would like to thank Bob for his dedication and commitment to Newron since he joined the Board in 2013. During his time at Newron, amongst other milestones achieved, we have seen the approval and launch of our Parkinson’s disease product Xadago(R) in key territories including the EU, the USA and Japan, and the advancement of our pipeline product Evenamide into potentially pivotal studies in patients suffering from schizophrenia. He leaves with our sincere thanks and best wishes for the future.’

Robert Leslie Holland is a member of the Company’s R&D Committee. At this time, Newron does not anticipate making any Non-Executive Director appointments.

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago(R)/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, the United Arab Emirates and Japan, and is commercialized by Newron’s Partner Zambon. US WorldMeds currently holds the commercialization rights in the USA and has entered into a definitive agreement to sell its Xadago rights, along with other CNS assets, to Supernus Pharmaceuticals. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories.  Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information

Newron
Stefan Weber – CEO, +39 02 6103 46 26, pr@newron.com

UK/Europe  
Simon Conway/ Natalie Garland-Collins, FTI Consulting, +44 (0)20 3727 1000,SCnewron@fticonsulting.com
 
Switzerland
Valentin Handschin, IRF Reputation, +41 43 244 81 54, handschin@irf-reputation.ch
 
Germany/Europe
Anne Hennecke/Caroline Bergmann, MC Services, +49 211 52925220, newron@mc-services.eu
 
USA
Paul Sagan, LaVoieHealthScience, +1 617 374 8800, Ext. 112, psagan@lavoiehealthscience.com


End of ad hoc announcement


show this